Aarti Drugs Ltd saw its shares jump 6% after the company reported a robust financial performance for the March quarter of FY25. As of 9:16 AM, the shares were trading 4.89% higher at Rs 367.00.
The pharmaceutical major posted a 32.7% year-on-year rise in net profit to ₹62.9 crore, up from ₹47.4 crore in the same quarter last year, driven by healthy demand and improved volumes.
Revenue for Q4 FY25 grew by 9.2% to ₹677 crore, compared to ₹620 crore in the corresponding period of the previous fiscal. The growth highlights strong operational performance and sustained market demand in both domestic and export markets.
Earnings before interest, taxes, depreciation, and amortization (EBITDA) came in at ₹93.4 crore, marking an 8.9% YoY increase from ₹85.8 crore. Despite the growth in profitability, the EBITDA margin remained stable at 13.8%, indicating persistent cost pressures that limited margin expansion.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
